CPhI North America finalising approach to 2020 event

The CPhI North America team has been working hard to actively monitor the COVID-19 situation and as it stands, we do not plan to further postpone or cancel our event, which will take place on the rescheduled dates of 9-11 September 2020.

The wellbeing of our community remains our top priority and as an Organized Gathering we will be implementing the World Health Organization’s recommended measures for gatherings, as well as following the steps advised by local health authorities.

As restrictions are lifted, we will have a better idea of the best-in-class biosecurity measures that we can adopt, as well as the alternative models that will best serve our community, with your wellbeing at the heart of our decision making.

We will continue to keep you updated as we learn more and formulate plans to ensure that CPhI North America remains the go-to event for the USA’s pharmaceutical industry. 

The CPhI North America team thanks you for your continued support and understanding during this time.

CPhI North America facilitates opportunities for learning & industry-defining partnerships


7 strategic zones, 1 massive expo hall, the entire pharma supply chain charged to do business


3 theaters, 3 topics: Drug Manufacturing - Drug Delivery & Development - BioProduction

Who you know matters...

Connect with the best minds in the North American pharma industry, and forge business relationships that last.

Source innovative solutions

Source innovative pharma solutions from the region and beyond in convenient product-specific zones

Immerse yourself in great content

 3 content theaters will host conferences and technical seminars in three tracks: Drug Manufacturing, Drug Development, BioProduction.

Get the Latest

Bioprocess and Continuous Manufacturing

Bioprocess and Continuous Manufacturing

Biopharma comprises 25% of the total pharma market and revenues have gone up by over 6000% from the 1990s to now. What are companies doing to keep up with this growth and innovation? Read this article to find out. 

The Future of Drug Development and Delivery

The Future of Drug Development and Delivery

How is biopharma striking a balance between modernizing drug development & delivery and the effort to rein in R&D expenses? While change is unlikely to be quick, there is consensus that pharma does need to embrace changes in drug development and delivery fully explore the wide range of opportunities that exist. 

Looking beyond the one-shop-stop hype: what really drives CDMOs

What really drives CDMOs

Pipeline diversification, emerging therapies and shifting customer demands are the real dynamics reshaping the contract manufacturing market, according to experts. Almost every article written about contracting reports that demand for outsourced manufacturing services is growing and states that the CDMO sector is consolidating.

In Other News

How Empathy Can Inspire Great Leadership

How Empathy Can Inspire Great Leadership

What role does empathy play in building successful teams, and in turn, businesses? Read on to find out how empathetic leadership promotes a strong corporate culture, and lays a strong foundation for success. 

Artificial Intelligence: Moving beyond efficiency gains in drug development

AI: Moving beyond efficiency gains in drug development

The utilisation of artificial intelligence (AI) by the pharmaceutical industry is gathering pace rapidly. The technology has evolved beyond simple neural networks and machine learning towards a deep learning approach geared at producing insights which should in theory enable better business decision making.

US Pharma Outlook

US Pharma Outlook

The new decade has rolled in, bringing new and unprecedented challenges. New products with shorter lifecycles, aging population and rigorous regulatory scrutiny will play a role in shaping the industry. In this article, leading industry experts in the region share their views on what the most important trends will be for this year, and this decade

Unlocking the potential of cannabinoid-derived drugs

The potential of cannabinoid-derived drugs

FDA approval of GW Pharmaceuticals’ Epidiolex® is widely considered to be a landmark in cannabinoid-derived drug development. Not only is Epidiolex® the first FDA-approved drug that contains a purified drug substance (cannabidiol) derived from the Cannabis sativa plant (marijuana), but it is also the first FDA approved drug for the treatment of patients with a rare and severe form of childhood epilepsy, Dravet syndrome.

What you can expect at CPhI North America

No matter where you are in the pharmaceutical supply chain, CPhI North America’s expo hall has you covered. It’s an expansive marketplace uniting pharma buyers and sellers, strategically positioned in seven unique zones.

Make the Most of the Event

Conferences you don't want to miss

Not one, but three conference theatres have been integrated into the show floor for the first time and will present great content on latest trends, challenges and solutions in these tracks - Drug Manufacturing, Drug Development, and Bioproduction (in collaboration with BioProcessing International.)

Meet your (business) match!

The Live Pharma Connect Match & Meet portal automatically matches you with exhibitors offering just the products and solutions you’re looking for. You can prearrange meetings with the companies that are relevant to you and optimize your three days at the show.